To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02116894
Title Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Acronym REGAL-1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Herbert Hurwitz, MD
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Duke Cancer Center, Duke University Medical Center Durham North Carolina 27710 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field